Regardless of what caused RP’s removal and subsequent lawsuit, this is not a good look for CYDY as it approaches a couple of huge milestones. My hope is that new investors see the value in Leronlimab and disregard the issues with RP, as those issues don’t change what leronlimab offers in HIV and what it could offer in cancer, NASH, and GvHD. But this is OTC land and it’s not hard to spin this lawsuit into some crazy store and scare those invested.

Best thing we can do is continue to post honest evaluations of the available information here on IH. Many here have done that already and pointed out that this lawsuit has nothing to do with the effectiveness of leronlimab and that the lawsuit tells us that big pharm and big investors are interested in CYDY.